Society News
-
Results From the AENEAS2 Trial Point to a New Frontline Treatment Option for NSCLC
Research team led by Dr. Shun Lu presents aumolertinib with chemotherapy as an additional first-line treatment option during the 2025 AACR Annual Meeting.
-
Beamion LUNG-01 Trial Results Support Zongertinib’s Potential as a First-Line Therapy
Dr. John V. Heymach says the latest findings suggest zongertinib may address an unmet need for patients with HER2-mutant NSCLC.
-
A Real Tail in These Curves: A Look at Advances and Future Directions in SCLC
During a recent address at SCLC 2025, Dr. Charles Rudin discussed the progress being made in reducing the incidence of small cell lung cancer and in treating it.
-
COCOON Regimen Demonstrates Improvement in Dermatologic Toxicities
Dr. Nicolas Girard recently presented data that shows prophylactic treatment with oral and topical antibiotics and ceramide-based moisturizer significantly reduced adverse skin events.
-
Savolitinib Plus Osimertinib Offers Hope for Addressing Resistance, Progression
Dr. Myung-Ju Ahn said recent data from SAVANNAH show the combination produced a meaningful and durable response in patients whose cancer progressed after osimertinib.
-
Final MARIPOSA Analysis Confirms OS Improvement Versus Osimertinib Monotherapy
Drs. Chih-Hsin Yang and Pérol reviewed the latest findings and key takeaways during a presentation at the European Lung Cancer Congress.
-
Pathology Researcher Keith Kerr Receives 2025 Heine H. Hansen Award
During his award lecture at the European Lung Cancer Congress, Dr. Kerr said lung cancer treatment has benefited from the bridging of the historical divide between pathology and medical oncology.
-
Foritinib Gains Momentum in China for ALK-positive NSCLC
China’s NMPA accepts a marketing authorization application for foritinib following interim results from the phase III REMARK trial.
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
Anti-obesity medications could theoretically reduce the absorption of oral TKIs, particularly in cases of lipophilicity, where therapeutic agents have a strong dependence on dietary fat for adequate dissolution.
-
Zipalertinib Meets Primary Endpoint in Phase 2b Trial
The drug’s developers have said the data show a positive overall response rate in previously treated patients with NSCLC with EGFR exon 20 insertion mutations.
View ILCN Archives
Provider Resources